

Edition 2025

CLINICAL DECISION MAKING TOOLKIT

Instant guidance for diagnosis, risk stratification and management







The Clinical Decision Making Toolkit

is produced by the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology (ESC).

This toolkit is supported by Boston Scientific and Inari Medical in the form of an unrestricted financial support. The scientific programme has not been influenced in any way by its sponsor.









The Association for Acute CardioVascular Care Clinical Decision-Making TOOLKIT

Héctor Bueno, M.D., PhD., FESC Editor in Chief

Jorge Nuche, M.D., PhD. Associate Editor

ISBN: 978-2-9537898-7-4




ACUTE HEART FAILURE


4.1 GENERAL APPROACH T J. Masip, F.H. Verbrugge	O ACUTE HEART FAILURE	p.:
4.2 CARDIOGENIC SHOCK —		p.1:

ACUTE HEART FAILURE: Initial approach

Assess vital parameters (BP, HR, SpO2, RR) & establish venous access



ACUTE HEART FAILURE: Clinical profiles



Cold sweaty extremities, Oliguria, Dizziness, Mental confusion, Narrow pulse pressure

> Dyspnoea, orthopnoea, Bendopnoea Paroxysmal nocturnal dysponea, Hypoxaemia

> Peripheral oedema, Jugular venous distention Thirds space, Hepatomegaly, Ascites

Pulmonary: ↑ PCWP

Systemic: ↑ CVP

P.7

ACUTE HEART FAILURE: Diagnosis and causes

1. Symptoms

- Dyspnoea
- · Exercise intolerance
- Fatigue

- Orthopnoea/ Bendopnoea
- Cough
- · Rapid weight gain

2. Signs

- Tachypnoea, tachycardia, hepatomegaly JVD or elevated CVP
- S3/S4, Pulmonary rales
- Third space: Leg oedema, Ascites, Pleural effusion

3. 12-lead electrocardiogram

- · Search for wide QRS, hypertrophy, Q waves, other
- . Exclude Arrhythmia and Acute Coronary Syndrome

4. Oxigenation / Blood gases

- · SpO2 in all patients
- ABG / VBG if significant respiratory or circulatory failure

5. Chest X-ray or lung ultrasound

Assess pulmonary congestion & identify pleural effusions

6. Laboratory - Natriuretic peptide levels

Blood count, electrolytes, creatinine, troponin, glucose, CRP, TSH, liver enzymes. Natriuretic peptides: exclude AHF if NTproBNP <300 pg/mL or BNP <100 pg/mL


7. Point-of-care ultrasonography

- . Echocardiography: cavity dimensions, LV / RV /function,
- Valvular dysfunction, E/A, E/E', IVC, RV-RA Δ, pericardium
- VExUS

Acute heart failure triggers


- C = Acute Coronary Syndrome
- H = Hypertension Emergency
- \mathbf{A} = Lifethreatening Arrhythmia
- $\mathbf{M} = \mathbf{M}$ echanical Complication
- P = Pulmonary Embolism
- I = Infection with Sepsis
- T = Cardiac Tamponade
- · Excessive salt intake
- . Non-adherence with GDMT
- Drugs (e.g. NSAIDs, negative inotropic drugs, cardiotoxic or nephrotoxic drugs)
- Excessive sympathetic drive
- Metabolic/hormonal cause (e.g. Thyroid dysfunction, adrenal dysfunction)
- Pregnancy & peripartum
- Neurological insult

ACUTE HEART FAILURE with Respiratory failure (SpO₂ < 90%)



DS

ACUTE HEART FAILURE with Circulatory failure



ACUTE HEART FAILURE: Treating congestion

Cardiac filling proceures

	Normal	Elevated	
No signs of fluid overload	TARGET	Vasodilators Consider: Revascularization Fix valve lesions	Loop diur
Signs of fluid overload (oedema, ascites, pleural effusion, 3th space)	SLOW DIURESIS	RAPID DIURESIS	Bolus de Bolus fr fluid over

Cardiac filling proceures


iretic therapy

- enous
- dose 1 with worse kidney function
- frequency 1 and dose1 with more erload

<u> </u>				
ADMISSION		EUVOLEMIA		DISCHARGE
GDMT: BB & ACEi/ARNi loop diuretics			Oral loop diuretics	
Assess adequate diuretic response urine output >150 mL/h AND urine Na concentration >80 mmol/L	Thiazides for diuretic resistan	ce	GDMT: BB & ACEI/AR	!Ni
Acetazolemide for faster decongestion 8	prevention of diuretic resistance			

MRA & SGLT2i

ACUTE HEART FAILURE: General course and management




HEART FAILURE DRUGS in the immediate postacute phase (0-48 h)

Renin-angiotensin blockers • Stop or downtitrate in case of: - Hypotension (MAP <60-65 mmHg)	,
 AKI with oliguria (<0.5 mL/Kg/h) eGFR < 20 mL/min/1.73m² [K+] > 5.5 mmol/L Otherwise maintain current dose Consider starting/uptitration if MAP >70 mmHg 	
Beta blockers • Stop or downtitrate in case of hypoperfusion with low CO or HR <50-55 bpm • Otherwise maintain current dose • Consider starting/uptitrate after adequate decongestion if no hypotension or HR<50 bpm	
• Continue or start if hemodynamic stability, eGFR >30 mL/min/1.73m² and [K+] <4.8 mmol/L • Stop if eGFR <20 mL/min/1.73m² or [K+] >5.5 mmol/L	
ISGLT-2 inhibitors • Continue or start if hemodynamic stability and eGFR >20 mL/min/1.73m² • Be wary of euglycaemic keto-acidosis, especially when gastro-intestinal symptoms present	
• If no reversible trigger or improvement in the GDMT, consider increased doses • If improvement in the GDMT & adequate decongestion, consider reduced doses	
Other vasodilators • Stop in case of hypotension with SBP <100 mmHg	
Other rate controlling drugs (digoxin, amiodarone, non-dihydropyridine CCB, ivabradine) • Stop in case of significant or symptomatic bradicardia	
Thrombosis prophylaxis • Maintain unless bleeding diathesis or oral anticoagulation	

P.13

LV pump failure is the primary insult in most forms of CS, but other parts of the circulatory system contribute to shock with inadequate compensation or additional defects




This protocol should be initiated as soon as cardiogenic shock/end organ hypoperfusion is recognised and should not be delayed pending intensive care admission


P.14

	and should not be delayed pending intensive care admission.					
EMERGENCY DEPARTMENT	0 min 5 min		EARLY TRIAGE & MONITORING Start O ₂ Establish i.v. access • Standard transthoracic echocardiogram to assess left (and right) ventricular function and for the detection of potential mechanical complications following MI	Age: 65-74, ≥75 Heart rate >100 beats per minute Systolic blood pressure <100 mmHg Proportional pulse pressure ≥25 % (Cl <2.2 l/min/m²) Orthopnea (PCWP >22 mmHg) Tachypnea (>20/min), >30/min (!) Killip class IV Clinical symptoms of tissue hypoperfusion/hypoxia: -cool extremities		
15 min 60 min	Arterial and a central venous catheterization with a catheter capable of measuring central venous oxygen saturation Early coronary angiography in specialized myocardial intervention centre when signs and/or symptoms of coronary myocardial intervention centre when signs and/or symptoms of the coronary myocardial intervention.	CORRECT: hypoglycemia & hypocalcemia, TREAT: sustaned arrhythmias: brady- or tachycardia Isotonic saline - 200-300 ml over 30 min period to achieve a central venous pressure of 8 to 12 mmHg or until perfusion improves (with a maximum of 500 ml) CONSIDER ADDITIONAL RESPIRATORY SUPPORT (HFNC, NIV) for comfort (fatigue, distress) or as needed: To correct acidosis NOTROPIC SUPPORT (dobutamine, levosimendan and/or vasopressor support)				
	60 min	CARDIAC INTENSIVE		TREATMENT GOALS • a mean arterial pressure of 60 mmHg or above, • a mean pulmonary artery wedge pressure of 18 mmHg or below, • a central venous pressure of 8 to 12 mmHg, • a urinary output of 0,5 ml or more per hour per kilogram of body weight • an arterial pH of 7.3 to 7.5 • a central venous saturation (ScvO₂) ≥70% (provided SpO₂≥93% and Hb level≥9 g/dl)		
				In persistent drug-resistant cardiogenic shock, consider mechanical circulatory support		

CARDIOGENIC SHOCK: Management




CARDIOGENIC SHOCK: Mechanical Circulatory Support




- The available devices differ in terms of the insertion technique, mechanical properties, and mode of action.
- A minimal flow rate of 70ml/kg/min, representing a cardiac index of at least 2,5L/m² is generally required to provide adequate organ perfusion. This flow is the sum of the mechanical circulatory support output and the remaining function of the heart (accounting for the fact that native heart output will decrease after device implantation).

CARDIOGENIC SHOCK: Selection of Modality



CARDIOGENIC SHOCK: What device when?



CARDIOGENIC SHOCK: Mechanical Ventilation

- FiO2 set per PaO2, typically start 50-100%
- PEEP >5 cm H20, typically 7-12 cm H20
- Titration by:
 - PEEP-FiO2 table OR
 - Decremental PEEP trial (best compliance) OR
- PV loops (between lower and higher inflection point) OR
- Esophageal pressure (end-expiratory transpulmonary pressure 0-5 cm H20)
- Beware hemodynamic effects:
 - Decreases LV afterload
 - Decreases venous return (preload)
 - Increases RV afterload if set inadequately high
- Minute Volume (7-10 ml/kg if no fever): Tidal volume X frequency
- Tidal volume: 6-8 ml/kg IBW
- Predicted body weight calculation:
- Male: 50 + 0.91 (height in cm 152.4)
- Female: 45.5 + 0.91 (height in cm 152.4)
- Driving Pressure < 15 cm H20
- Plateau Pressure > 30 cm H20

Pressure (assist) controle (more comfortable on low sedation, safe for plateau pressure) vs Volume (assist) controle (shorter breaths in obstructive patients, less quarantee for safe plateau pressure)

CARDIOGENIC SHOCK: RRT and Indications

- . SLED (hemodialysis) vs CRRT: depends mainly on local options
- CRRT: hemofiltration (higher blood flows) vs hemodiafiltration (lower blood flows)
- Early vs late: generally early not shown to be beneficial, but some suggestions for populations with benefit (eg, ELAIN trial was positive and was constituted for 50% by cardiac surgery patients).

INDICATIONS:

- A) Maintainance/correction of intravascular volume (low dose possible): inadequate diuretic response in hypervolemic patients, despite high dose IV diuretics
- B) Correction of underlying acid-base/ion disturbance (High dose needed):
 - Acidosis (pH <7,1; beware: very limited elimination of lactic acid compared to production)
 - Hyperkalemia
 - Hyperphosphatemia
 - Uremic signs (pericarditis, encephalopathy)
- C) Elimination of Toxins (consider adding hemadsorption for some):
 - · Anti-epileptics
 - Metformin
 - Lithium
 - Some beta-blockers (atenolol, metoprolol, sotalol)...

SUGGESTED INITIAL SETTINGS CVVH:

- Blood flow 150-200 ml/min
- Dose 25 ml/kg/h of effluent
- Ultrafiltration depending on need for fluid removal between 0-1000 ml/h (usually 0-500 ml/h)

P.20

Abbreviations

APTT = Activated partial thromboplastin time

AB = Airway and breathing

ABG = Arterial blood gas

AADs = Antiarrhythmic drugs

AAS = Acute aortic syndrome

ACEI = Angiotensin converting enzyme inhibitor

ACLS = Advanced cardiovascular life support

ACS = Acute coronary syndrome

ACT = Activated clotting time

AD = Aortic Dissection

AED = Automated external defibrillator

AF = Atrial fibrillation

ANA = Antinuclear antibodies

Ao = Aortic

aPTT = Activated partial thromboplastin time

ARB = Angiotensin receptor blockers

AS = Aortic stenosis

AV = Atrioventricular

AVB = Atrioventricular conduction block

AVN = Atrioventricular node

AVNRT = Atrioventricular nodal re-entrant

tachycardia

AVNT = Atrioventricular nodal tachycardia

BID = Twice a day

BBB = Bundle branch block

BLS = Basic life support

BNP = Brain natriuretic peptide

BP = Blood pressure

CABG = Coronary artery bypass grafting

CAD = Coronary artery disease

Cath Lab = Catheterisation laboratory

CCB = Calcium channel blockers

CCU = Coronary care unit

CHF = Congestive heart failure

CMR = Cardiovascular magnetic resonance

COPD = Chronic obstructive pulmonary disease

CPAP = Continuous positive airway pressure

CPR = Cardiopulmonary resuscitation

Cr = Creatinine blood level (mg/dL)

CrCI = Creatinine clearance

CRP = C-reactive protein

CS = Cardiogenic shock

CSM = Carotid sinus massage

CSNRT = Corrected sinus node recovery time

P.22

Abbreviations (Cont.)

CSS = Carotid sinus syndrome
CT = Computed tomography

CT-angio = Computed tomography angiography

cTn = Cardiac troponin

CUS = Compression venous ultrasound

CV = Cardiovascular

CVA = Cerebrovascular accident

CXR = Chest X-ray

DAPT = Dual antiplatelet therapy

DD = Dyastolic dysfunction **DM** = Diabetes mellitus

dTT = Diluted thrombin time

DVT = Deep vein thrombosis

ECG = Electrocardiogram

Echo = Echocardiogram

ECMO = Extracorporeal membrane oxygenation

ECT = Ecarin clotting time

ED = Emergency department

EF = Ejection fraction **EG** = Electrograms

eGFR = Estimated glomerular filtration rate

 $(mI/min/1.73 m^2)$

EMB = Endomyocardial biopsy

EMS = Emergency medical services

EPS = Electrophysiological study

ERC = European Resuscitation Council ESR = Erythrocyte sedimentation rate

ETT = Exercice treadmill testing

FFP = Fresh frozen plasma

FMC = First medical contact

GER = Gastroesophageal reflux

GFR = Glomerular flow rate

GI = Gastrointestinal

GP = Glycoprotein **Hb** = Haemoglobin

HF = Heart failure

HIT = Heparin-induced thrombocytopenia

HOCM = Hypertrophic obstructive cardiomyopathy

HTN = Hypertension

HR = Heart rate

hsTn = High-sensitive troponin

IABP = Intra-aortic balloon pump

ICC = Intensive cardiac care

ICCU = Intensive cardiac care unit

Abbreviations (Cont.)

ICD = Implantable cardioverter defibrillator

ICI = Immune checkpoint inhibitors

IHD = Ischemic heart disease

IMH = Intramural hematoma

IRF = Immediate-release formulation

ISFC = International Society and Federation

of Cardiology

i.o. = Intraosseous

IV = Invasive ventilation

i.v. = Intravenous

KD = Kidney disease

LBBB = Left bundle branch block

LD = Loading dose

LGE = Late gadolinium enhancement LMWH = Low-molecular weight heparin

LOC = Loss of consciousness

LV = Left ventricular

LVAD/Bi-AD = left ventricular, bi-ventricular assist

LVD = Left ventricular dysfunction

LVEF = Left ventricular ejection fraction

LVH = Left ventricular hypertrophy

LVSD = Left ventricular systolic dysfunction

MCS = Mechanical circulatory support

MD = Maintenance dose

MDCT = Computed tomography with >4 elements

MI = Myocardial infarction

MRA = Mineralocorticoid receptor antagonist

MRI = Magnetic resonance imaging
Mvo = Microvascular obstruction

NIV = Non-invasive ventilation

NOAC = New oral anticoagulants

NSAID = Non-steroidal anti-inflammatory drugs NSVT = Non-sustained ventricular tachycardia

or recurrent

NSTE-ACS = Non ST-segment elevation

acute coronary syndrome

NSTEMI = Non ST-segment elevation myocardial

infarction

NTG = Nitroglycerin

NT-proBNP = N-terminal pro brain natriuretic

peptide

NVAF = Non-valvular atrial fibrillation

NYHA = New York Heart Association

OH = Orthostatic hypotension

PAP = Pulmonary arterial pressure

PAU = Penetrating aortic ulcer

PCI = Percutaneous coronary intervention

PCM = Physical counter-measures

PCP = Pulmonary capillary pressure

PE = Pulmonary embolism

PEA = Pulmonary endarterectomy

PEEP = Positive end expiratory pressure

PPC = Prothrombin complex concentrate

PR = Pulmonary regurgitation

PRECISE-DAPT = PREdicting bleeding

Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet

Therapy

PRF = Prolonged-release formulation

ProCT = Procalcitonin

PRN = Pro re nata

PS-PEEP = Pressure support-positive endexpiratory pressure

PSVT = Paroxysmal supraventricular tachycardia

QD = Once a day

QPM = Every evening

rFVIIa = Recombinant factor VIIa

rtPA = Recombinant tissue plasminogen activator

RV = Right ventricular

RVOT-VT = Right ventricular outflow tract

ventricular tachycardia

SBP = Systemic blood pressure

s.c = Subcutaneous

SIRS = Systemic inflammatory response syndrome

SLE = Systemic lupus erythematosus

SMU = Syncope management units

STE-ACS = ST-segment elevation acute

coronary syndrome

STEMI = ST-segment elevation myocardial infarction

SVT = Supraventricular tachycardia

Spo₂ = Oxygen saturation

TEE = Transesophageal echocardiography

TEVAR = Thoracic endovascular aortic repair

TIA = Transient ischemic attack

TID = Three times a day

TLOC = Transient loss of consciousness

TOE = Transoesopageal echocardiography

Abbreviations (Cont.)

TSH = Thyroid-stimulating hormone

TTE = Transthoracic echocardiography

UA = Unstable angina

UFH = Unfractionated heparin

ULN = Upper limit of normal

VBGA = venous blood gas analysis

VF = Ventricular fibrillation

VR = Vascular resistance

VT = Ventricular tachycardia

VTE = Venous thromboembolism

VVS = Vasovagal syncope

WBC = white blood cell count

WHO = World Health Organization

WPW = Wolff-Parkinson-White

Be at the heart of your community

Become an ACVC Member





The ACVC supports you

all year long



Textbook & Handbooks



ACVC Congress



>7,500 members



European Heart Journal - Acute Cardiovascular Care





Global Network of National Representatives



Certification



Disclaimer and Copyrights

This is a publication of the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology (ESC). Its content reflects the opinion of the authors based on the evidence available at the time it was written and does not necessarily imply an endorsement by ACVC or the ESC.

The guidance suggested in the Clinical Decision Making Toolkit does not override the individual responsibility of the healthcare professional to make appropriate decisions according to each patient's circumstances and profile, as well as local regulations and licenses.

Some content, illustrations/tables/figures were inspired and/or adapted from ESC Guidelines and other existing sources, with permission granted by the original publishers.

Acknowledgements

We are indebted to all the authors for their commitment and for the strong effort to synthesise their wide scientific knowledge and clinical experience into simple algorithms and schemes using the aim to help clinicians in everyday clinical practice in the easiest possible manner as the main driver of their work.

The support of this initiative by the Association for Acute CardioVascular Care (ACVC) board members was essential to launch this initiative as was the hard work of the ESC staff to make this project move forward.

March 2025





